2022 World Conference on Lung Cancer (ePosters)-EP08.01-039. Impact of Pulmonary Function Indexes on Immunotherapy Efficacy in Lung Adenocarcinoma Patients and the Potential Prognostic Factors

EP08.01-039. Impact of Pulmonary Function Indexes on Immunotherapy Efficacy in Lung Adenocarcinoma Patients and the Potential Prognostic Factors

Back to course

Pdf Summary

This study aimed to investigate the relationship between pulmonary function indexes and the efficacy of immunotherapy in lung adenocarcinoma patients. A retrospective study was conducted on 188 patients who received immunotherapy. The patients were divided into two groups based on the median value of the FEV1/FVC ratio. The primary endpoint was progression-free survival (PFS), and the secondary endpoint was overall survival (OS). <br /><br />The results showed that the FEV1/FVC77% group had a significantly longer median PFS compared to the FEV1/FVC77% group. The hazard ratio for PFS in the FEV1/FVC77% group was 0.507, indicating a lower risk of progression in this group. However, there was no significant difference in median OS between the two groups.<br /><br />Multivariate analysis revealed that the FEV1/FVC value, diffusion function, smoking status, KRAS mutation status, and line of immunotherapy were independent prognostic factors for PFS. Additionally, FEV1/FVC77%, normal ventilatory function, abnormal diffusion function, and first-line immunotherapy were identified as independent predictive factors for better OS.<br /><br />The study concluded that pulmonary function indexes were associated with survival outcomes in lung adenocarcinoma patients treated with immunotherapy. The FEV1/FVC value was identified as a potential prognostic factor for clinical outcomes.<br /><br />Overall, this study highlights the importance of evaluating pulmonary function indexes in predicting the efficacy of immunotherapy in lung adenocarcinoma patients. Identifying patients with favorable pulmonary function may help in selecting appropriate treatment strategies for better clinical outcomes.

Asset Subtitle

Fang Hu

Meta Tag

Speaker Fang Hu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

pulmonary function indexes

immunotherapy

lung adenocarcinoma

retrospective study

FEV1/FVC ratio

progression-free survival

overall survival

hazard ratio

multivariate analysis

prognostic factors